SANAZ MAHDAVI: Open Payments
NPI 1528808300 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 43 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $389 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 13 | $706 |
| JAZZ PHARMACEUTICALS INC. | 11 | $268 |
| SK Life Science, Inc. | 8 | $265 |
| Eisai Inc. | 2 | $64 |
| CATALYST PHARMACEUTICALS, INC. | 2 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| Otter Pharmaceuticals, LLC | 1 | $36 |
| CSL Behring | 1 | $30 |
| Biogen, Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $22 |
Products named: EPIDIOLEX, Fintepla, XCOPRI, Leqembi, Briviact, FYCOMPA, KESIMPTA, SYMPAZAN.
Industry payments across TX — which companies pay providers there.
